NASDAQ:ARCT - Arcturus Therapeutics Stock Price, Forecast & News

Arcturus Therapeutics trades on the NASDAQ under the ticker symbol "ARCT."

Arcturus Therapeutics Ltd (NASDAQ:ARCT) announced its quarterly earnings data on Monday, May, 13th. The biotechnology company reported ($0.68) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.53) by $0.15. The biotechnology company had revenue of $4.35 million for the quarter, compared to analysts' expectations of $3.47 million. Arcturus Therapeutics had a negative net margin of 63.05% and a negative return on equity of 160.16%. View Arcturus Therapeutics' Earnings History.

Arcturus Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, March 11th 2020. View Earnings Estimates for Arcturus Therapeutics.

Arcturus Therapeutics will be holding an earnings conference call on Wednesday, March 11th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

5 analysts have issued 1 year price objectives for Arcturus Therapeutics' stock. Their forecasts range from $18.00 to $24.00. On average, they anticipate Arcturus Therapeutics' share price to reach $19.75 in the next twelve months. This suggests a possible upside of 46.8% from the stock's current price. View Analyst Price Targets for Arcturus Therapeutics.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcturus Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Arcturus Therapeutics.

News coverage about ARCT stock has been trending extremely negative on Thursday, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Arcturus Therapeutics earned a coverage optimism score of -4.2 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the near term. View News Stories for Arcturus Therapeutics.

Arcturus Therapeutics saw a decrease in short interest in February. As of February 14th, there was short interest totalling 148,400 shares, a decrease of 5.8% from the January 30th total of 157,500 shares. Based on an average daily trading volume, of 74,900 shares, the days-to-cover ratio is presently 2.0 days. Approximately 1.8% of the company's stock are sold short. View Arcturus Therapeutics' Current Options Chain.

Some companies that are related to Arcturus Therapeutics include Rhythm Pharmaceuticals (RYTM), Radius Health (RDUS), Cytokinetics (CYTK), Dova Pharmaceuticals (DOVA), Stoke Therapeutics (STOK), Amphastar Pharmaceuticals (AMPH), Portola Pharmaceuticals (PTLA), CannTrust (CNTTF), Collegium Pharmaceutical (COLL), Aprea Therapeutics (APRE), DiaMedica Therapeutics (DMCAF), Phoenix Tree (IMAB), Homology Medicines (FIXX), Frequency Therapeutics (FREQ) and ANI Pharmaceuticals (ANIP).

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcturus Therapeutics investors own include Opko Health (OPK), Energy Transfer LP Unit (ET), Corbus Pharmaceuticals (CRBP), KLA (KLAC), Inovio Pharmaceuticals (INO), AbbVie (ABBV), Abeona Therapeutics (ABEO), Amicus Therapeutics (FOLD), Novavax (NVAX) and Viking Therapeutics (VKTX).

Arcturus Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include ARK Investment Management LLC (9.14%), Dfpg Investments LLC (3.01%), Nikko Asset Management Americas Inc. (1.85%), Sumitomo Mitsui Trust Holdings Inc. (1.85%), Geode Capital Management LLC (0.56%) and Credit Suisse AG (0.39%). Company insiders that own Arcturus Therapeutics stock include Andy Sassine, Joseph E Payne, Magda Marquet and Peter C Farrell. View Institutional Ownership Trends for Arcturus Therapeutics.

ARCT stock was sold by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., EAM Investors LLC, Renaissance Technologies LLC and Dfpg Investments LLC. View Insider Buying and Selling for Arcturus Therapeutics.

ARCT stock was purchased by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, Credit Suisse AG, Bank of Montreal Can, Acadian Asset Management LLC, Goldman Sachs Group Inc., Geode Capital Management LLC and Tower Research Capital LLC TRC . Company insiders that have bought Arcturus Therapeutics stock in the last two years include Andy Sassine, Joseph E Payne, Magda Marquet and Peter C Farrell. View Insider Buying and Selling for Arcturus Therapeutics.

Shares of ARCT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ARCT stock can currently be purchased for approximately $13.45.

Arcturus Therapeutics has a market capitalization of $203.61 million and generates $15.75 million in revenue each year. The biotechnology company earns $-21,780,000.00 in net income (profit) each year or ($2.16) on an earnings per share basis. Arcturus Therapeutics employs 72 workers across the globe.View Additional Information About Arcturus Therapeutics.

The official website for Arcturus Therapeutics is http://www.arcturusrx.com/.

Arcturus Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-900-2660 or via email at [email protected]